Evidence level: B
中医九种体质不是”有没有效”的问题,而是”多少量、对谁有效”的问题——剂量-反应曲线与应答者分层,是把体质学说变成精准干预的两把钥匙。
正文
中医体质学说认为,人分九种体质——平和质与八种偏颇质(气虚、阳虚、阴虚、痰湿、湿热、血瘀、气郁、特禀)——每种体质对应不同的疾病易感性。近年来大量研究证实,体质与肠道菌群密切相关:2021 年一项从 5185 人筛出的阳虚质 RCT 发现,阳虚质人群的菌群多样性显著低于平和质,而中药干预后菌群”部分恢复到平和质样水平”(PMID 34107861)。2023 年一项九体质菌群比较研究更进一步:八种偏颇质各有独特的菌群指纹,平和质的 FMT 供体合格率显著更高,其菌群在小鼠身上表现出更强的抗肥胖效应(PMID 41853345)。
但体质能否被”剂量”控制?
现代医学的答案藏在益生菌的剂量-反应研究里。2023 年一项五组剂量 RCT(2×10⁷、2×10⁹、2×10¹⁰、2×10¹¹ CFU/天 + 安慰剂)用副干酪乳杆菌 K56 干预肥胖成人 60 天,结果呈现出典型的倒 U 型曲线:2×10⁹ CFU 组体脂率、内脏脂肪面积、糖化血红蛋白显著下降,菌群多样性改善;而最高剂量 2×10¹¹ CFU 组不仅没有额外获益,体重反而出现回升趋势(PMID 36944956)。这意味着菌群干预不是”越多越好”——存在一个疗效峰值的”黄金剂量”,超过它效果反而衰减。从中医”过犹不及”的角度看,这个倒 U 型曲线几乎是五行”太过与不及皆为病”的现代翻版:剂量不足达不到改变偏颇状态的门槛,剂量过高则可能打破菌群自身的生态平衡,触发代偿性反馈。
这一现象在系统综述层面同样成立。2017 年一篇剂量-反应系统综述明确指出:益生菌的剂量-反应关系是终点特异的——抗生素相关腹泻呈现明确的正向剂量-反应,而便秘、IBS 等终点则没有检出稳定剂量-反应(PMID 28008787)。也就是说,”有效剂量”不能跨终点套用,必须针对具体目标(如体质量表评分)单独绘制曲线。这对体质研究是重要的方法论警示:既往文献若只报道”某种体质菌群干预有效”,却未说明剂量区间与终点定义,其结论的可复制性就要打折扣。
值得注意的是,剂量-反应曲线并非只由剂量一个变量决定。菌株特异性同样关键:不同菌株在肠道定植能力、代谢产物谱(如短链脂肪酸、胆汁酸)上差异巨大,同一 CFU 剂量下生物学效应可以相差一个数量级。这意味着”九体质×多剂量”试验必须在固定菌株的前提下做剂量梯度,否则剂量与菌株两个变量会互相混淆,画出的曲线毫无意义。
比剂量更关键的问题:谁应答?
即便是同一剂量,也不是人人有效。2022 年一篇 IBS-D 益生菌 RCT 的事后分析发现,应答者仅占 25%,且应答者与无应答者的基线菌群组成显著不同——通过基线粪便菌群数据可以预测个体是否会对益生菌治疗产生应答(PMID 36250371)。这解释了为什么许多菌群干预试验的平均效应被”无应答者”稀释:不是干预无效,而是没有分层。反过来想,这恰恰是中医体质学说最值钱的地方——它提供的正是一套几千年经验沉淀下来的”应答者分层”体系。
中医的九体质问卷(CCMQ)本质上就是一种低成本分层工具。2024 年葛根芩连汤 120 人 T2DM 双盲 RCT 显示,中药降糖效应由 Faecalibacterium 富集介导(PMID 38495337)——同样是”同一干预、不同菌群背景、不同应答”的模式。把这两条线合起来,就构成一个可检验的科学蓝图:
“九体质 × 多剂量梯度”头对头试验——按 CCMQ 分型入组(平和/痰湿/湿热/阳虚等主要体质),每种体质随机分配 2-3 个剂量梯度菌群干预 + 安慰剂,双终点(体质量表复评 + 菌群指纹监测):
1. 体质特异的剂量-反应曲线:痰湿质与阳虚质是否在同一菌株上呈现不同的峰值剂量?
2. 应答者-无应答者分层:基线体质量表评分 + 菌群指纹能否预测应答?
3. 与九体质菌群指纹对接:2023 年研究已提供八种偏颇质的基线菌群参考谱(PMID 41853345),可作为分层依据。
这个设计若实现,将首次把”体质-菌群-剂量-应答”四个变量放进同一个因果框架,把中医”因人施治”翻译成可测量的个体化剂量曲线。
证据与局限
已验证: 益生菌存在剂量-反应关系,且呈现倒 U 型(K56 五组剂量 RCT,10⁹ CFU 峰值效应,PMID 36944956);应答者-无应答者可用基线菌群预测(IBS-D post hoc,PMID 36250371);阳虚质/痰湿质有菌群特征与干预 RCT 证据(PMID 34107861、38495337);九体质菌群指纹有全谱系比较(PMID 41853345)。
部分验证: 剂量-反应是终点特异的(系统综述 PMID 28008787)——”体质量表评分”这一终点尚无专属剂量-反应曲线;体质×剂量的交互效应仅有零散线索(K56 试验未做体质分层)。
待验证: 九体质×多剂量梯度的头对头 RCT;体质特异的峰值剂量是否存在;基线体质量表评分能否作为低成本应答预测因子;应答者菌群标志物(如 Faecalibacterium)是否跨体质稳定。
相关阅读
证据等级: B(剂量-反应与应答者分层各有 PubMed 直接证据,但”九体质×多剂量梯度”合一试验尚不存在,属科学类比+间接证据)
参考文献: PMID 36944956, PMID 28008787, PMID 36250371, PMID 34107861, PMID 38495337, PMID 41853345
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
Gut Microbiota Intervention Alters the Dose-Response Curve and Responder Stratification in the Nine Constitution Types: A Scientific Blueprint for Multiple Dose Gradients
Evidence level: B
The nine TCM constitutions are not a question of “whether effective,” but rather “how much and for whom.” Dose-response curves and responder stratification serve as two keys to transforming constitution theory into precise intervention.
Main Text
TCM constitution theory posits that humans fall into nine constitutions—the Harmonious Constitution and eight deviant types (Qi-deficiency, Yang-deficiency, Yin-deficiency, Phlegm-Dampness, Damp-Heat, Blood Stasis, Qi Stagnation, and Special Predisposition)—each corresponding to distinct disease susceptibilities. Recent studies have confirmed a strong correlation between constitution and gut microbiota: a 2021 RCT screening 5,185 individuals found that the Yang-deficient constitution group exhibited significantly lower microbiota diversity compared to the Harmonious group, with herbal intervention partially restoring diversity to “Harmonious-like levels” (PMID 34107861). A 2023 comparative study of nine constitutions advanced this finding: each of the eight deviant types possesses a unique microbiota fingerprint, the Harmonious donor had a significantly higher FMT qualification rate, and its microbiota demonstrated stronger anti-obesity effects in mice (PMID 41853345).
But can constitution be controlled by “dose”?
The modern medical answer lies within probiotic dose-response research. A 2023 five-arm dose RCT (2×10⁷, 2×10⁹, 2×10¹⁰, 2×10¹¹ CFU/day + placebo) using Lactobacillus paracasei K56 in obese adults for 60 days revealed a classic inverted U-shaped curve: the 2×10⁹ CFU group showed significant reductions in body fat percentage, visceral adipose area, and HbA1c alongside improved microbiota diversity; conversely, the highest dose group (2×10¹¹ CFU) yielded no additional benefit and exhibited a trend toward weight regain (PMID 36944956). This indicates that microbial intervention is not “more is better”—there exists a “gold dose” representing an efficacy peak, beyond which effects attenuate. From the TCM perspective of “excess and deficiency both cause disease,” this inverted U-shaped curve mirrors the modern iteration of Five Phases where “too much and too little are both pathological.” Insufficient dosage fails to reach the threshold for altering deviant states, while excessive dosage may disrupt the microbiota’s own ecological balance, triggering compensatory feedback mechanisms.
This phenomenon holds true at the systematic review level as well. A 2017 dose-response systematic review explicitly stated that the probiotic dose-response relationship is endpoint-specific: antibiotic-associated diarrhea showed a clear positive dose-response, whereas endpoints like constipation and IBS did not reveal stable dose-response relationships (PMID 28008787). Thus, an “effective dose” cannot be applied across endpoints; curves must be drawn individually for specific targets (e.g., body mass index scores). This serves as a critical methodological warning for constitution research: prior literature reporting “effective intervention for a certain constitution” without specifying dosage ranges or endpoint definitions suffers from reduced reproducibility.
Notably, the dose-response curve is not determined solely by dosage. Strain specificity is equally critical: different strains vary greatly in gut colonization capacity and metabolite profiles (e.g., short-chain fatty acids, bile acids), resulting in biological effects differing by an order of magnitude at the same CFU dose. Consequently, “Nine Constitutions × Multi-Dose” trials must be conducted under fixed strains to establish dose gradients; otherwise, the confounding of dosage and strain variables renders the resulting curve meaningless.
A more critical question than dose: Who responds?
Even at identical doses, not everyone responds. A post-hoc analysis of a 2022 IBS-D probiotic RCT revealed that responders accounted for only 25%, and responders differed significantly from non-responders in baseline microbiota composition—baseline fecal microbiota data can predict individual response to probiotic therapy (PMID 36250371). This explains why average effects in many microbial intervention trials are diluted by “non-responders”: the intervention is not ineffective, but lacks stratification. Conversely, this highlights the most valuable aspect of TCM constitution theory—it provides a millennia-old empirical framework for “responder stratification.”
The TCM nine-constitution questionnaire (CCMQ) is essentially a low-cost stratification tool. A 2024 double-blind RCT of 120 patients with T2DM treated with Ge Gen Qin Lian Tang showed that the herbal hypoglycemic effect was mediated by the enrichment of Faecalibacterium (PMID 38495337)—a pattern of “same intervention, different microbiota background, different response.” Merging these two lines forms a testable scientific blueprint:
“Nine Constitutions × Multi-Dose Gradient” Head-to-Head Trial—enrollment stratified by CCMQ (Harmonious, Phlegm-Dampness, Damp-Heat, Yang-deficiency, etc.), random allocation of 2–3 dose gradient microbial interventions + placebo for each constitution type, with dual endpoints (BMI re-evaluation + microbiota fingerprint monitoring):
1. Constitution-specific dose-response curves: Do Phlegm-Dampness and Yang-deficient constitutions exhibit different peak doses on the same strain?
2. Responder vs. Non-responder stratification: Can baseline BMI scores + microbiota fingerprints predict response?
3. Alignment with Nine-Constition Microbiota Fingerprints: The 2023 study provided baseline microbiota reference spectra for the eight deviant types (PMID 41853345), serving as a stratification basis.
If realized, this design would be the first to place “constitution-microbiota-dose-response” within a single causal framework, translating TCM’s “treating according to the individual” into measurable individualized dose curves.
Evidence and Limitations
Verified: Probiotics exhibit a dose-response relationship with an inverted U-shape (K56 five-arm dose RCT, peak effect at 10⁹ CFU, PMID 36944956); responder vs. non-responder status can be predicted by baseline microbiota (IBS-D post hoc, PMID 36250371); Yang-deficient/Phlegm-Dampness constitutions have microbiota characteristics and intervention RCT evidence (PMID 34107861, 38495337); nine-constitution microbiota fingerprints have full-spectrum comparison (PMID 41853345).
Partially Verified: Dose-response is endpoint-specific (systematic review PMID 28008787)—no dedicated dose-response curve exists yet for “BMI score”; interaction effects between constitution and dosage remain scattered clues (K56 trial did not stratify by constitution).
To Be Verified: Head-to-head RCT for Nine Constitutions × Multi-Dose Gradients; existence of constitution-specific peak doses; whether baseline BMI scores serve as low-cost response predictors; stability of responder microbiota markers (e.g., Faecalibacterium) across constitutions.
Related Reading
- Dose-Response RCT for Constitution-Oriented Microbiome Intervention
- Head-to-Head RCT: Selecting Strains by Constitution vs. One-Size-Fits-All Intervention
- Validation of Deviant Phenotype Transfer in Germ-Free Mice via FMT Based on TCM Constitution
- Biofrequency Codes (P3)
Evidence Level: B (Direct PubMed evidence exists for dose-response and responder stratification, but a unified trial for “Nine Constitutions × Multi-Dose Gradient” does not yet exist; relies on scientific analogy and indirect evidence)
References: PMID 36944956, PMID 28008787, PMID 36250371, PMID 34107861, PMID 38495337, PMID 41853345
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.
Leave a Reply